News and information about universal access to health care; the impact of restrictive policies and financial challenges on access to treatment; drug stock-outs; and scaling up services.

Access to medicines and treatment: latest news

Access to medicines and treatment resources

Access to medicines and treatment features

Access to medicines and treatment news from aidsmap

More news

Access to medicines and treatment news selected from other sources

  • Medicare decides against tighter management of HIV drugs

    The Department of Health and Human Services will continue barring Medicare Part D plans from applying the drug utilization management tools prior authorization and step therapy for beneficiaries taking HIV antiretroviral drugs. A rule proposed in November 2018 would have permitted such practices. Gilead voiced opposition to the original proposal, saying physicians need to have the flexibility to prescribe the right medicines for patients.

    22 hours ago | BioPharma Dive
  • Mexican official resigns as HIV drug shortage sparks outcry

    A top Mexican health official said on Thursday that he had resigned amid growing anger over drug shortages that have left hundreds of HIV patients without life-saving medicines.

    10 May 2019 | Reuters
  • Gilead Will Donate Truvada to U.S. for H.I.V. Prevention

    Officials at the Department of Health and Human Services said the donation came about “as a result of discussions between the Trump administration and Gilead.” Critics said it would not be enough to end the AIDS epidemic and questioned the company’s motives.

    10 May 2019 | The New York Times
  • Generic HIV prevention drug coming in 2020, Gilead says

    "Gilead reached an agreement with Teva Pharmaceuticals in 2014 to allow the early launch of a generic version of Truvada into the market in 2020, a year earlier than required," wrote Douglas Brooks, Gilead's executive director for community engagement, in an email shared with NBC News by the advocacy group PrEP4All.

    09 May 2019 | CNBC
  • Official Statement responding to Gilead Sciences’ announcement that it will allow Teva to Manufacture a Generic Version of Truvada

    While Gilead’s announcement that generic Truvada will be made available in the United States a year early is a victory for the LGBTQ+ community, for HIV activists, and for U.S. taxpayers, this should only be the beginning. Even their announcement today leaves Gilead with exclusive rights to Truvada as PrEP for another 15 months and Teva as the only generic manufacturer on the U.S. market. This will do little to reduce the price in a way that will increase access and PrEP4All remains suspicious of the terms and lack of transparency surrounding the Teva settlement.

    09 May 2019 | Breakthepatent.org
  • Group Of Developed Countries Seek To Delay Italian Proposal On Drug Price Transparency

    A number of developed countries are working to delay a landmark proposal at the World Health Organization by Italy to increase transparency of drug prices and R&D costs in an effort to make medicines more affordable, according to sources. The Italian proposal has garnered a number of supporters, including within Europe; but at an informal WHO consultation today and last week at the European Union, countries such as Germany, France, and the United Kingdom have begun pushing for postponement of discussions, sources said.

    07 May 2019 | Health Policy Watch
  • Zimbabwean patients on ARV treatment have to take expired medicines

    People living with HIV in Zimbabwe who are on antiretroviral treatment have been given expired medication. They say this is contrary to the treatment protocol and endangers lives.

    07 May 2019 | Daily Maverick
  • HIV Medical Providers Strongly Oppose Proposed Changes To Medicare Drug Plan’s “Protected Classes”

    The proposed rule would allow plans to exclude certain drugs in those protected classes, including antiretrovirals.

    25 April 2019 | Poz
  • Confidentiality breaches, stigma and a lack of time are stopping men in Côte d’Ivoire from getting tested and treated for HIV

    Interviews with men in Côte d’Ivoire reveal radical differences in the perceptions of those who do and don’t access care. Research, published in PLOS ONE, found many of the worries of men out of care are not reflected in the experiences of those with regular contact with services. Men’s perceptions were linked with their level of engagement with HIV care, with men who have regular contact with HIV testing and treatment services displaying more positive attitudes than those with little or no contact with such services. The paper can be seen at https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211385

    24 April 2019 | AVERT
  • Thousands feared at risk after Mexico reforms HIV+ regime

    Thousands of Mexicans living with HIV or at risk of infection could be left without life-saving services after the government changed the way it funds treatment, according to public health experts and LGBT+ rights advocates.

    18 April 2019 | Reuters
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.